Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cei/uxaf004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravenous Efgartigimod Alfa as Initial Monotherapy for Disabling Ocular Myasthenia in an Elderly Patient with Multiple Comorbidities.
Cureus
November 2024
Neurology, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, USA.
Myasthenia gravis (MG) is one of the most common neuromuscular disorders. It is an antibody-mediated autoimmune disease affecting the neuromuscular junction, presenting with fluctuating muscle weakness that commonly affects the ocular, bulbar, proximal, and respiratory muscles. Treating MG in the older population with preexisting comorbidities can be challenging.
View Article and Find Full Text PDFAuthor Correction: Structural basis for antibody-mediated NMDA receptor clustering and endocytosis in autoimmune encephalitis.
Nat Struct Mol Biol
November 2024
Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
New insights into the use of high dose corticosteroids and plasmapheresis in persons with MOGAD and NMOSD.
Mult Scler Relat Disord
December 2024
Department of Clinical Neurological Sciences, University of Western Ontario, University Hospital 339 Windermere Road, London Ontario N6A 5A5 Canada. Electronic address:
Background: Anti-myelin oligodendrocyte glycoprotein associated disease (MOGAD) and neuromyelitis optica spectrum disease (NMOSD) are antibody mediated diseases characterized by neurological symptoms including recurrent relapses of optic neuritis and/or myelitis, as well as other less frequent syndromes. The current treatment for acute attacks of NMOSD/MOGAD are based on clinical studies for other demyelinating diseases(i.e.
View Article and Find Full Text PDF[Preparation and preliminary identification of Fc-silent anti-human CD36 chimeric antibody].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
October 2024
The Key Medical Laboratory of Guangzhou, Guangzhou Blood Center, Guangzhou 510095, China. *Corresponding author, E-mail:
Objective To prepare a Fc-silent chimeric antibody against human CD36 and analyse its bioactivity and phagocytic effect on CD36(+) platelets. Methods The genes encoding V and V fragments of the monoclonal antibody (mAb) 32-106 were obtained through RNA extraction from hybridoma cell lines, PCR amplification and sequence analysis. By using gene synthesis and recombination techniques, the vectors expressing light and heavy chains of the chimeric antibody against human CD36 were constructed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!